Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization

Vulvovaginal candidiasis (VVC) is considered as the second most common cause of vaginitis after bacterial vaginosis. About three quarters of women of reproductive age have a history of at least one episode of VVC, and about a half of women have two or more episodes. Candida albicans is responsible f...

Full description

Bibliographic Details
Published in:Медицинский совет
Main Authors: A. Yu. Romanov, A. G. Syrkasheva, I. V. Kuznetsova
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-10-01
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/6401
_version_ 1857118464799408128
author A. Yu. Romanov
A. G. Syrkasheva
I. V. Kuznetsova
author_facet A. Yu. Romanov
A. G. Syrkasheva
I. V. Kuznetsova
author_sort A. Yu. Romanov
collection DOAJ
container_title Медицинский совет
description Vulvovaginal candidiasis (VVC) is considered as the second most common cause of vaginitis after bacterial vaginosis. About three quarters of women of reproductive age have a history of at least one episode of VVC, and about a half of women have two or more episodes. Candida albicans is responsible for85% to 90% of vulvovaginal candidiasis. There are uncomplicated and complicated forms of VVC. Uncomplicated forms are not severe cases caused by C. albicans. Complicated forms are cases caused by other Candida species, severe cases, cases that develop during pregnancy or associated with other diseases such as diabetes mellitus or immunosuppressive conditions. Reccurent cases are also complicated ones. Therapeutic schemes should depend on the form of the VVC. Short-term topical therapy or a single oral dose are effective in 90% of uncomplicated cases. Complicated forms of VVC require longer treatment. Oral fluconazole can be administered three times with a break of 72 hours. Topical azoles can be administered daily for at least 1 week. So, sertaconazole in the form of suppositories is used once intravaginally. The data on the use of probiotics in the treatment of VVC today are contradictory and heterogeneous. Treatment of VVC during pregnancy, especially in the first trimester, may be associated with adverse perinatal outcomes. On the other hand, during pregnancy, VVC can be more severe than in non-pregnant women, especially in the second half of pregnancy. In addition, the risk of transmission to a newborn is about 50%. Thus, the identification and treatment of VVC is one of the important tasks in pregnancy planning, including assisted reproduction.
format Article
id doaj-art-e1d79cbf44b6492fa55e98f59d58e5d2
institution Directory of Open Access Journals
issn 2079-701X
2658-5790
language Russian
publishDate 2021-10-01
publisher Remedium Group LLC
record_format Article
spelling doaj-art-e1d79cbf44b6492fa55e98f59d58e5d22025-08-19T19:09:58ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-10-01013778310.21518/2079-701X-2021-13-77-835773Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilizationA. Yu. Romanov0A. G. Syrkasheva1I. V. Kuznetsova2Kulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyKulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyHigher Medical SchoolVulvovaginal candidiasis (VVC) is considered as the second most common cause of vaginitis after bacterial vaginosis. About three quarters of women of reproductive age have a history of at least one episode of VVC, and about a half of women have two or more episodes. Candida albicans is responsible for85% to 90% of vulvovaginal candidiasis. There are uncomplicated and complicated forms of VVC. Uncomplicated forms are not severe cases caused by C. albicans. Complicated forms are cases caused by other Candida species, severe cases, cases that develop during pregnancy or associated with other diseases such as diabetes mellitus or immunosuppressive conditions. Reccurent cases are also complicated ones. Therapeutic schemes should depend on the form of the VVC. Short-term topical therapy or a single oral dose are effective in 90% of uncomplicated cases. Complicated forms of VVC require longer treatment. Oral fluconazole can be administered three times with a break of 72 hours. Topical azoles can be administered daily for at least 1 week. So, sertaconazole in the form of suppositories is used once intravaginally. The data on the use of probiotics in the treatment of VVC today are contradictory and heterogeneous. Treatment of VVC during pregnancy, especially in the first trimester, may be associated with adverse perinatal outcomes. On the other hand, during pregnancy, VVC can be more severe than in non-pregnant women, especially in the second half of pregnancy. In addition, the risk of transmission to a newborn is about 50%. Thus, the identification and treatment of VVC is one of the important tasks in pregnancy planning, including assisted reproduction.https://www.med-sovet.pro/jour/article/view/6401vulvovaginal candidiasispregnancyassisted reproductioncandida albicanssertaconazole
spellingShingle A. Yu. Romanov
A. G. Syrkasheva
I. V. Kuznetsova
Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
vulvovaginal candidiasis
pregnancy
assisted reproduction
candida albicans
sertaconazole
title Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
title_full Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
title_fullStr Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
title_full_unstemmed Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
title_short Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
title_sort treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization
topic vulvovaginal candidiasis
pregnancy
assisted reproduction
candida albicans
sertaconazole
url https://www.med-sovet.pro/jour/article/view/6401
work_keys_str_mv AT ayuromanov treatmentofvulvovaginalcandidiasisinpreparationprogramsforinvitrofertilization
AT agsyrkasheva treatmentofvulvovaginalcandidiasisinpreparationprogramsforinvitrofertilization
AT ivkuznetsova treatmentofvulvovaginalcandidiasisinpreparationprogramsforinvitrofertilization